Global Ulcerative Colitis (UC) Market Growth, Trends and Forecasts (2019-2024) – ResearchAndMarkets.com
June 4, 2019DUBLIN–(BUSINESS WIRE)–The “Global
Ulcerative Colitis (UC) Market Growth, Trends and Forecasts (2019-2024)”
report has been added to ResearchAndMarkets.com’s
offering.
The ulcerative colitis market was valued at USD 6,854.47 million in
2018, and is also expected to register a CAGR of 4.86% during the
forecast period (2019-2024).
Ulcerative colitis (UC) is the most common form of inflammatory bowel
disease which affects several people. From a global perspective, several
research studies in 2018 have reported annual incidence rates of UC
ranging from 0.5 to 24.5 cases per 100,000 people.
On the other hand, incidences have been increasing in Asian and South
European countries. In the United States, UC affects an estimated
500,000 people and is the cause of 250,000 doctor visits and 30,000
hospitalizations, each year. UC has an uneven presence in major
geographical regions across the world.
It is common in most of Europe and North America and uncommon in most of
the developing Asian countries. UC is more prevalent among males and has
a regional north-to-south variation. One potential explanation is the
differences in exposure to ultraviolet light, resulting in relative
vitamin D deficiency in countries close to the Arctic. People who live
in lower latitudes are more likely to develop UC than those in higher
latitudes.
According to the Centers for Disease Control and Prevention (CDC), in
2015, 1.3% of US adults (3 million) reported that they were diagnosed
with IBD (either Crohn’s disease or UC). This was a large increase in
number from 1999 (0.9% or 2 million adults).
According to an article published in PubMed, the highest reported
prevalence values were in Europe (UC – 505 per 100,000 people in Norway,
Crohn’s disease – 322 per 100,000 people in Germany) and North America
(UC – 286 per 100,000 people in the United States, Crohn’s disease – 319
per 100,000 people in Canada). The high prevalence of the disease is
driving the market.
Key Market Trends
-
Ulcerative Proctitis Segment Expected to Experience the Fastest Growth
during the Forecast Period -
North America Region Holds the Largest Market Share and is Believed to
Follow the Same Trend over the Forecast Period
Competitive Landscape
The ulcerative colitis market consists of several major players,
including AbbVie Inc., Merck Co., Johnson and Johnson, and many others.
The companies are implement certain strategic initiatives, such as
merger, new product launch, acquisition, and partnerships that help them
in strengthening their market position.
For instance, in May 2018, Takeda Pharmaceutical Company Limited and
Shire PLC announced that they reached an agreement on the terms of a
recommended offer pursuant to which Takeda will acquire the entire
issued and to be issued ordinary share capital of Shire.
Key Topics Covered
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Global Incidence and Prevalence of Ulcerative Colitis
4.2.2 New Product Launches in the Market
4.2.3 Increase in Patient Assistance Programs
4.3 Market Restraints
4.3.1 High Levels of Unmet Clinical Need in Ulcerative Colitis (UC)
4.3.2 Side-effects of Medications
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 Drug Type
5.1.1 Anti-Inflammatory Drugs
5.1.1.1 Aminosalicylates
5.1.1.2 Corticosteroids
5.1.2 Anti-TNF biologics
5.1.3 Immunosuppressant
5.1.4 Calcineurin Inhibitors
5.1.5 Other Drug Types
5.2 By Disease Type
5.2.1 Ulcerative Proctitis
5.2.2 Proctosigmoiditis
5.2.3 Left-sided Colitis
5.2.4 Pancolitis or Universal Colitis
5.2.5 Fulminant Colitis
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Bausch Health Companies Inc. (Salix Pharmaceutical)
6.1.3 Boehringer Ingelheim GmbH
6.1.4 Johnson and Johnson
6.1.5 Merck & Co.
6.1.6 Novartis AG
6.1.7 Shire
6.1.8 Takeda Pharmaceuticals
6.1.9 Teva Pharmaceuticals Ltd.
6.1.10 Pfizer Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/cvh7z8
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs, Gastrointestinal
Drugs